MTMelih Tutuncu

Melih Tutuncu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Melih Tutuncu has a total of 213 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

    by Bade Gulec, Elif Everest, Melih Tutuncu, Ugur Bilge, Sabahattin Saip, Ugur Uygunoglu, Aksel Siva

    Background: Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap. Some patients remain double‐seronegative, showing atypical features that challenge current classifications. Objective: To better characterize the phenotypic spectrum of antibody‐negative atypical inflammatory demyelinating disorders (AIDD) using unsupervised clustering. Methods: We retrospectively analyzed 316 patients (MS = 164, AQP4 + NMOSD = 36, double‐seronegative NMOSD = 21, MOGAD = 15, AIDD = 80) followed between 2010 and 2023. Principal component analysis and k‐means clustering were applied to AIDD cases using clinical, demographic, and radiological data. Results: AIDD patients had lower disability and fewer corpus callosum and posterior fossa lesions than MS and NMOSD. Three clusters emerged: (1) myelitis‐predominant with unmatched CSF oligoclonal bands and longitudinally extensive spinal lesions, (2) brainstem‐dominant with recurrent brainstem attacks, and (3) optic neuritis‐dominant with recurrent LEON meeting MS dissemination criteria. Treatment patterns differed; rituximab was most frequent. Conclusion: Double‐seronegative AIDD represents a heterogeneous clinical spectrum. Unsupervised clustering provides a data‐driven framework for refining phenotypic classification and may support biomarker and therapeutic development in antibody‐negative CNS demyelination.

  • Open Access

    Real-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder

    by Emine Rabia Koc, Mehmet Fatih Yetkin, Furkan Saridas, Omer Faruk Turan, Serhan Sevim, Murat Terzi, Sedat Sen, Melih Tutuncu, Ugur Uygunoglu, Murat Kurtuncu, et al.

    Objective: To evaluate the real-world effectiveness and safety of eculizumab in patients with AQP4-IgG–positive neuromyelitis optica spectrum disorder (NMOSD) and to identify predictors of disability outcomes. Methods: This multinational, retrospective cohort study analyzed data from 46 patients across 26 centers. The outcomes included the annualized relapse rate (ARR), relapse-free status, change in expanded disability status scale (EDSS) scores, and adverse events. To identify predictors of EDSS improvement or worsening, patients were stratified into subgroups (improved vs. stable/worsened) at each follow-up time point and compared based on demographic, clinical, and radiological variables. Results: This retrospective cohort study included 46 patients with AQP4-IgG-positive NMOSD from 26 centers, followed for a mean of 27.3 months. The mean ARR significantly decreased from 1.1 in the 2 years pre-treatment to 0.1 during eculizumab therapy. The relapse-free rate increased from 6.5% pre-treatment to 80.4%. Mean EDSS scores improved from 4.2 at baseline to 3.6 at 24 months. The presence of area postrema syndrome was associated with a favorable prognosis, while the presence of spinal attacks was associated with a poor prognosis at 12 months. Adverse events occurred in 7 patients (18.9%), leading to permanent discontinuation in only two. Conclusion: Eculizumab demonstrated robust real-world effectiveness in reducing relapse rates and stabilizing disability, with an acceptable safety profile. Clinical outcomes may be influenced by attack phenotype, underscoring the importance of early intervention.


  • Treatment Adherence in a Large Cohort of Turkish Multiple Sclerosis Population

    by Meral Seferoğlu, Bilge Piri Çınar, Ülgen Yalaz Tekan, Fatma Avşar, Pınar Yiğit, Ali Özhan Sıvacı, Serkan Demir, Melih Tütüncü, Haluk Gümüş, Cihat Uzunköprü, et al.

    Objectives This study aimed to evaluate adherence to disease-modifying therapies (DMTs) among patients with multiple sclerosis (MS) and to identify factors influencing compliance, based on perceptions and preferences of both patients and neurologists. Methods Questionnaires were designed by a team of experts, including MS specialists, psychologists, and statisticians, to capture data on treatment adherence and related factors. A total of 1021 MS patients and their neurologists participated. Patients' adherence to oral, injectable, and infusion DMTs was assessed alongside demographic and disease-related characteristics. Results The study included 1021 MS patients with a mean age of 35.69 ± 9.07 years. Infusion therapies demonstrated the highest adherence rates (96.6%). Among all patients, 78.9% maintained treatment without interruption, while 56.7% of those who interrupted therapy informed their physicians. Patients with a disease duration of less than one year or more than 10 years exhibited lower rates of treatment interruption compared to those with a disease duration of 1–10 years (p = 0.032). In the injectable DMT group, significant differences in adherence were noted (p < 0.001). The lowest interruption rate (13.5%) was seen in patients with a disease duration of less than one year, whereas interruption rates were markedly higher (83%) in those with a duration exceeding 16 years. Conclusion Improving adherence requires a patient-centered, collaborative approach emphasizing shared decision-making between physicians and patients. Addressing factors that contribute to non-compliance is essential for optimizing treatment outcomes and enhancing long-term disease management in MS.


  • Open Access

    Evaluation of nonmotor symptoms in myasthenia gravis patients

    by Aysel Tekeşi̇n, Çağla Şi̇şMan, Ufuk Emre Toprak, Alena Sar, Burcu Akalin, Goncagül Koşargeli̇r, Meli̇h Tütüncü, Enes Yi̇ğİt

    Background/aim: Myasthenia gravis (MG) is chronic autoimmune disorder characterized primarily by muscle weakness and fatigue, due to autoantibodies targeting acetylcholine receptor at neuromuscular junction. In this study, we aimed to evaluate non-motor symptoms in myasthenia gravis patients and compare them with disease duration, severity and clinical features.Materials and methods: This prospective study was conducted with thirty-five myasthenia gravis patients and thirty-five healthy volunteers. Total of 35 patients, 17 women and 18 men with mean age of 52.9±13.6 years constituted patient group. Control group consisted of total of 35 participants, 23 women and 12 men with mean age of 46.9±12.2 years. Patient group was applied scales of MG Foundation of America clinical classification, MG Composite and Turkish version of MG Quality of Life 15. For non-motor functions, both in patients and controls; we used the inquiry questionnaires evaluating symptoms of headache, pain, depression, anxiety, sleep, physical activity, cognition, smell and taste. Results: Results revealed prevalent and diverse non-motor symptoms in MG patients. Montreal Cognitive Assessment (MoCA) score and degree of olfactory function in cinnamon in patient group was significantly (p<0.05) lower than control group. Rate of impaired MoCA degree, headache rate, Beck depression score, depression rate, Beck anxiety score, anxiety rate, Pittsburgh Sleep Quality Index (PSQI) score, rate of poor PSQI in patient group was significantly (p<0.05) higher than control group.Conclusion: In conclusion, our study emphasizes importance of recognizing and managing non-motor symptoms in MG patients, advocating for multidisciplinary approach to care that addresses both motor and non-motor manifestations. By expanding our understanding of MG's systemic impact and exploring new treatment modalities, we can improve lives of those living with this complex autoimmune disorder. Further research is needed to elucidate pathogenic mechanisms underlying these non-motor manifestations, which will be pivotal in developing more targeted and effective therapeutic strategies.


  • Microstructural analysis of verbal fluency performance in relapsing-remitting multiple sclerosis based on the impact of disability level

    by Melis Buse Altun, Özlem Öge-Daşdöğen, Melih Tütüncü

    Verbal fluency (VF) evaluates language and cognitive abilities. This study compared VF in Relapsing-Remitting Multiple Sclerosis (RRMS) and healthy controls (HC), examining variables including correct responses (CR), mean cluster size (MCS), switches (S), and fluency difference score (FDS). RRMS participants were subgrouped by Expanded Disability Status Scale (EDSS), to explore the relationship between MS severity and VF. Twenty-four RRMS participants and matched HCs underwent Mini-Mental State Exam and VF Test. Statistical analysis compared VF between RRMS subgroups based on severity levels, and in HC. RRMS significantly impacted the CR, and S (CRSF p = 0.01, SSF p = 0.002; CRPF=0.002, SPF p = 0.002), while there was no significant difference in FDS between RRMS groups (p = 0.9). No significant relationship was found between EDSS scores, and VF subtests (CRSF p = 0.061, MCSSF p = 0.46, SSF p = 0.051, CRPF p = 0.521, MCSPF p = 0.966, SPF p = 0.599). In RRMS, our results demonstrate impairments in all VF parameters except the MCSSF+PF, and FDS. This study suggests that intact MCSSF+PF may reflect preserved verbal memory and word recall, while significant switching differences may indicate impaired cognitive flexibility. Similar FDS to those of HC suggest that no performance discrepancy in subtests in RRMS. Intact MCS might be a distinctive pattern in the early clinical stage of MS.


  • mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?

    by Melih Tütüncü, Serkan Demir, Gökhan Arslan, Öykü Dinç, Sedat Şen, Tuncay Gündüz, Cihat Uzunköprü, Haluk Gümüş, Mesude Tütüncü, Rüveyda Akçin, et al.


  • Ocrelizumab in pediatric multiple sclerosis

    by Ceren Bibinoğlu Amirov, Sema Saltık, Cengiz Yalçınkaya, Melih Tütüncü, Sabahattin Saip, Aksel Siva, Uğur Uygunoğlu


  • Prevalence of clinical manifestations and neuroimaging features in cerebral small vessel disease

    by Sedat Gez, Birsen İnCe, Melih Tütüncü, Güneş Kızıltan, Murat Tuğberk Bakar, Uygur Tanriverdi, Ayşegül Gündüz


  • Open Access

    Investigation of multiple sclerosis-related pathways through the integration of genomic and proteomic data

    by Elif Everest, Ege Ülgen, Ugur Uygunoglu, Melih Tutuncu, Sabahattin Saip, Osman Uğur Sezerman, Aksel Siva, Eda Tahir Turanli

    Background: Multiple sclerosis (MS) has a complex pathophysiology, variable clinical presentation, and unpredictable prognosis; understanding the underlying mechanisms requires combinatorial approaches that warrant the integration of diverse molecular omics data. Methods: Here, we combined genomic and proteomic data of the same individuals among a Turkish MS patient group to search for biologically important networks. We previously identified differentially-expressed proteins by cerebrospinal fluid proteome analysis of 179 MS patients and 42 non-MS controls. Among this study group, 11 unrelated MS patients and 60 independent, healthy controls were subjected to whole-genome SNP genotyping, and genome-wide associations were assessed. Pathway enrichment analyses of MS-associated SNPs and differentially-expressed proteins were conducted using the functional enrichment tool, PANOGA. Results: Nine shared pathways were detected between the genomic and proteomic datasets after merging and clustering the enriched pathways. Complement and coagulation cascade was the most significantly associated pathway (hsa04610, P = 6.96 × 10−30). Other pathways involved in neurological or immunological mechanisms included adherens junctions (hsa04520, P = 6.64 × 10−25), pathogenic Escherichia coli infection (hsa05130, P = 9.03 × 10−14), prion diseases (hsa05020, P = 5.13 × 10−13). Conclusion: We conclude that integrating multiple datasets of the same patients helps reducing false negative and positive results of genome-wide SNP associations and highlights the most prominent cellular players among the complex pathophysiological mechanisms.


  • A comprehensive assessment of patient experience and disease-related awareness in multiple sclerosis: A questionnaire-based nation-wide survey in Turkey

    by Serkan Demir, Melih Tutuncu, Cihat Uzunkopru, Haluk Gumus, Sedat Sen, Tuncay Gunduz, Ipek Gungor Dogan, Bilge Piri Cinar, Sila Usar Incirli, Mesude Tutuncu, et al.